Alectinib: Adjuvant Treatment for Lung Cancer Approved by US FDA
Alectinib approved by US FDA for auxiliary treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who underwent tumor resection.
Source: medindia.net